In a crossover trial of 19 patients with AChR-positive myasthenia gravis already taking pyridostigmine, pyridostigmine vs placebo improved the MG Impairment Index (mean difference 5.3, 95% CI 1.9-8.7); a post hoc model estimated lower societal costs.
Secondary analysisn = 19
Remijn-Nelissen et al. Efficacy of Pyridostigmine in Myasthenia Gravis: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial